# A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

> **NCT05817812** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Swedish Orphan Biovitrum** · enrollment: 93 (actual)

## Conditions studied

- Hemophilia A, Severe

## Interventions

- **DRUG:** Efanesoctocog alfa

## Key facts

- **NCT ID:** NCT05817812
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-07-31
- **Primary completion:** 2026-05-22
- **Final completion:** 2026-06-12
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817812, "A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05817812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*